Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab with or without single-fraction SABR for advanced non-small cell lung cancer after prior chemotherapy
ACTRN12616000352404Phase 2Terminated
- Sponsor
- University of Sydney
- Start
- Mar 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of nivolumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by University of Sydney. Primary endpoint: Progression-free survival at 6 months. Started Mar 2017; status: terminated.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ACTRN12616000352404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616000352404.